Skip Navigation
Skip to contents

Cancer Res Treat : Cancer Research and Treatment

OPEN ACCESS

Search

Page Path
HOME > Search
3 "Sung-Won Kim"
Filter
Filter
Article category
Keywords
Publication year
Authors
Funded articles
Original Articles
General
Attitudes toward Risk-Reducing Mastectomy and Risk-Reducing Salpingo-oophorectomy among Young, Unmarried, Healthy Women in Korea
Boyoung Park, Dongwon Kim, Jiyoung Kim, Bom Yi Lee, Junghyun Yoon, Sung-Won Kim
Cancer Res Treat. 2022;54(2):375-382.   Published online August 9, 2021
DOI: https://doi.org/10.4143/crt.2021.449
AbstractAbstract PDFPubReaderePub
Purpose
This study investigated the attitudes toward risk-reducing mastectomy (RRM) and risk-reducing salpingo-oophorectomy (RRSO) as cancer prevention options for BRCA1/2 carriers in healthy, young, unmarried Korean women.
Materials and Methods
A nationally representative sample of 600 women, aged 20-39 years, completed a questionnaire on sociodemographic variables, preference for genetic testing, and intention to undergo risk-reducing surgeries after receiving information on the cancer risk of BRCA1/2 mutations and benefits of risk-reducing surgeries.
Results
A total of 54.7% and 57.7% had the intention to undergo RRM and RRSO, respectively, on the assumption that they were BRCA1/2 carriers. Older age and no intention to undergo genetic testing were associated with a reduced likelihood of undergoing RRM (odds ratio [OR], 0.30; 95% confidence interval [CI], 0.14 to 0.61 for age 35-39 years and OR, 0.35; 95% CI, 0.20 to 0.62 for no intention for genetic testing) and RRSO (OR, 0.39; 95% CI, 0.19 to 0.79 for age 35-39 years and OR, 0.30; 95% CI, 0.17 to 0.53 for no intention for genetic testing). Women who chose to be single were likely to undergo risk-reducing surgeries (OR, 1.67; 95% CI, 1.07 to 2.60 for RRM and OR, 1.56; 95% CI, 1.00 to 2.44 for RRSO).
Conclusion
More than 50% of healthy, unmarried, young Korean women were inclined to undergo prophylactic surgeries if they were BRCA1/2 mutation carriers. Further studies on decision-making process for cancer prevention in individuals at high risk for cancer need to be conducted.

Citations

Citations to this article as recorded by  
  • A Scoping Review of Primary Breast Cancer Risk Reduction Strategies in East and Southeast Asia
    Filipa Alpeza, Christine Kim Yan Loo, Qingyuan Zhuang, Mikael Hartman, Serene Si Ning Goh, Jingmei Li
    Cancers.2025; 17(2): 168.     CrossRef
  • Impact of graphical display on the intention to undergo risk-reducing salpingo-oophorectomy and mastectomy in individuals positive for BRCA pathogenic variant
    Yoon-Jung Choi, Younju Park, Boyoung Park, Heejung Chae, So-Youn Jung, Kum Hei Ryu, Myong Cheol Lim, Soo Jin Park, Yoon Jung Chang, Sun-Young Kong
    Scientific Reports.2024;[Epub]     CrossRef
  • 5,762 View
  • 167 Download
  • 2 Web of Science
  • 2 Crossref
Close layer
Clinicopathological Features of Patients with the BRCA1 c.5339T>C (p.Leu1780Pro) Variant
Hyung Seok Park, Jai Min Ryu, Ji Soo Park, Seock-Ah Im, So-Youn Jung, Eun-Kyu Kim, Woo-Chan Park, Jun Won Min, Jeeyeon Lee, Ji Young You, Jeong Eon Lee, Sung-Won Kim
Cancer Res Treat. 2020;52(3):680-688.   Published online January 28, 2020
DOI: https://doi.org/10.4143/crt.2019.351
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
Recent studies revealed the BRCA1 c.5339T>C, p.Leu1780Pro variant (L1780P) is highly suggested as a likely pathogenic. The aim of this study was to evaluate clinicopathologic features of L1780P with breast cancer (BC) using multicenter data from Korea to reinforce the evidence as a pathogenic mutation and to compare L1780P and other BRCA1/2mutations using Korean Hereditary Breast Cancer (KOHBRA) study data.
Materials and Methods
The data of 54 BC patients with L1780P variant from 10 institutions were collected and the clinicopathologic characteristics of the patients were reviewed. The hereditary breast and/or ovarian cancer–related characteristics of the L1780P variant were compared to those of BC patients in the KOHBRA study.
Results
The median age of all patients was 38 years, and 75.9% of cases showed triple-negative breast cancer. Comparison of cases with L1780P to carriers from the KOHBRA study revealed that the L1780P patients group was more likely to have family history (FHx) of ovarian cancer (OC) (24.1% vs. 19.6% vs. 11.2%, p < 0.001 and p=0.001) and a personal history of OC (16.7% vs. 2.9% vs. 1.3%, p=0.003 and p=0.001) without significant difference in FHx of BC and bilateral BC. The cumulative risk of contralateral BC at 10 years after diagnosis was 31.9%, while the cumulative risk of OC at 50 years of age was 20.0%. Patients with L1780P showed similar features with BRCA1 carriers and showed higher penetrance of OC than patients with other BRCA1 mutations.
Conclusion
L1780P should be considered as a pathogenic mutation. Risk-reducing salpingo-oophorectomy is highly recommended for women with L1780P.

Citations

Citations to this article as recorded by  
  • Whole Exome-Wide Association Identifies Rare Variants in GALNT9 Associated with Middle Eastern Papillary Thyroid Carcinoma Risk
    Rong Bu, Abdul K. Siraj, Saud Azam, Kaleem Iqbal, Zeeshan Qadri, Maha Al-Rasheed, Saif S. Al-Sobhi, Fouad Al-Dayel, Khawla S. Al-Kuraya
    Cancers.2023; 15(17): 4235.     CrossRef
  • Feasibility of targeted cascade genetic testing in the family members of BRCA1/2 gene pathogenic variant/likely pathogenic variant carriers
    Jeeyeon Lee, Ji Yeon Ham, Ho Yong Park, Jin Hyang Jung, Wan Wook Kim, Byeongju Kang, Yee Soo Chae, Soo Jung Lee, In Hee Lee, Nan Young Lee
    Scientific Reports.2022;[Epub]     CrossRef
  • Molecular Characterization of BRCA1 c.5339T>C Missense Mutation in DNA Damage Response of Triple-Negative Breast Cancer
    Jeong Dong Lee, Won-Ji Ryu, Hyun Ju Han, Tae Yeong Kim, Min Hwan Kim, Joohyuk Sohn
    Cancers.2022; 14(10): 2405.     CrossRef
  • Discovery of BRCA1/BRCA2 founder variants by haplotype analysis
    Won Kyung Kwon, Hyeok-Jae Jang, Jeong Eon Lee, Yeon Hee Park, Jai Min Ryu, Jonghan Yu, Ja-Hyun Jang, Jong-Won Kim
    Cancer Genetics.2022; 266-267: 19.     CrossRef
  • Local Laboratory Testing of Germline BRCA Mutations vs. Myriad: A Single-Institution Experience in Korea
    Joohyun Hong, Jiyun Lee, Minsuk Kwon, Ji-Yeon Kim, Jong-Won Kim, Jin Seok Ahn, Young-Hyuck Im, Yeon Hee Park
    Diagnostics.2021; 11(2): 370.     CrossRef
  • Analysis of BRCA1/2 variants of unknown significance in the prospective Korean Hereditary Breast Cancer study
    Joo Heung Kim, Sunggyun Park, Hyung Seok Park, Ji Soo Park, Seung-Tae Lee, Sung-Won Kim, Jong Won Lee, Min Hyuk Lee, Sue K. Park, Woo-Chul Noh, Doo Ho Choi, Wonshik Han, Sung Hoo Jung
    Scientific Reports.2021;[Epub]     CrossRef
  • A Population-Based Analysis of BRCA1/2 Genes and Associated Breast and Ovarian Cancer Risk in Korean Patients: A Multicenter Cohort Study
    Kyung-Sun Park, Woochang Lee, Moon-Woo Seong, Sun-Young Kong, Kyung-A Lee, Jung-Sook Ha, Eun-Hae Cho, Sung-Hee Han, Inho Park, Jong-Won Kim
    Cancers.2021; 13(9): 2192.     CrossRef
  • 9,042 View
  • 187 Download
  • 7 Web of Science
  • 7 Crossref
Close layer
Objective Measurement of Cosmetic Outcomes of Breast Conserving Therapy Using BCCT.core
Tosol Yu, Keun-Yong Eom, Na Young Jang, Kyung Su Kim, Tae Ryool Koo, Jeanny Kwon, Byoung Hyuck Kim, Eunyoung Kang, Sung-Won Kim, Jae-Sung Kim, In Ah Kim
Cancer Res Treat. 2016;48(2):491-498.   Published online June 22, 2015
DOI: https://doi.org/10.4143/crt.2015.088
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
The purpose of this study is to evaluate objective cosmetic outcomes and factors related to breast-conserving therapy (BCT) using the BCCT.core software.
Materials and Methods
Fifty-one patients who received BCT with informed consent were evaluated using the BCCT.core software. Patients were divided into two groups based on the BCCT score: excellent or good (n=42) vs. fair or poor (n=9). Analysis of clinical factors was performed to determine factors affecting cosmetic outcomes.
Results
The objective cosmetic outcome of BCT measured using the BCCT.core software was excellent in 10% of patients, good in 72%, and fair in 18%. None of the patients were classified as poor outcome. Tumor characteristics, systemic adjuvant therapy (chemotherapy and hormonal therapy), and radiation dose or energy of electron boost did not show correlation with the score measured by the BCCT.core program (p > 0.05). In univariate analysis, maximum dose within the breast (Dmax), width of tangential field, and excised tumor volume were smaller in patients with excellent or good by the BCCT.core compared to those with fair or poor (Dmax, 110.2±1.5% vs. 111.6±1.7%, p=0.019; width of tangential field, 8.0±1.1 cm vs. 8.6±0.7 cm, p=0.034; excised tumor volume, 64.0±35.8 cm3 vs. 95.3±54.4 cm3, p=0.067). In multivariate analysis, only Dmax was a significant factor for breast cosmetic outcome with a risk ratio of 1.697 (95% confidence interval, 1.006 to 2.863; p=0.047).
Conclusion
Objective measurement of cosmetic outcome of BCT using the BCCT.core software was feasible. The cosmetic outcome of BCT may be affected by the maximum dose within the breast.

Citations

Citations to this article as recorded by  
  • Impact of autologous breast reconstruction on bra fit
    Yen-Tung Liu, Novera H. Khan, Mary Catherine Bordes, Gregory P. Reece, Ashleigh M. Francis, Tzuan A. Chen, Karen Bravo, Mia K. Markey
    Supportive Care in Cancer.2024;[Epub]     CrossRef
  • Easy Anthropometric Measurements Are Representative of Baseline Values of Breast Q Values in Asymptomatic Women
    Giuseppe Catanuto, Nicola Rocco, Concetta G. Fichera, Ada Cinquerrui, Martina Rapisarda, Paolo Chiodini, Francesca Magnoni, Patrizia Dorangricchia, Valeria Sebri, Gabriella Pravettoni, Maurizio Bruno Nava, Francesco Caruso
    Healthcare.2024; 12(2): 268.     CrossRef
  • Outcomes of reconstructive techniques in breast cancer using BCCT. core software
    Sevgi Kurt, Ahmet Serkan İlgün, Enver Özkurt, Gürsel Soybir, Gül Alço, Çağlar Ünal, Filiz Elbüken Çelebi, Tomris Duymaz, Tuğba Kayan Tapan, Naziye Ak, Çetin Ordu, Vahit Özmen
    World Journal of Surgical Oncology.2024;[Epub]     CrossRef
  • Evaluating intra and inter-observer bias in the cosmetic rating for random vs. serial assessment of breast photographs
    Preeti Belani, Rima Pathak, Shraddha Kenekar, Gaurika Pokale, Pallavi Rane, Ashwini Chalke, Tabassum Wadasadawala
    The Royal College of Radiologists Open.2024; 2: 100152.     CrossRef
  • Comparison of Postoperative Breast Asymmetry Using Vectra 3D Imaging in Prepectoral Versus Subpectoral Implant-Based Breast Reconstruction
    Seung-Ho Choi, Sang-Oh Lee, Kyu-Jin Chung, Il-Kug Kim, Jun-Ho Lee
    Journal of Clinical Medicine.2024; 13(23): 7486.     CrossRef
  • Long-term Efficacy and Cosmetic Outcomes of Partial-breast Irradiation Using Multicatheter Interstitial Brachytherapy for Breast-conserving Therapy
    Kazuhiko SATO, Hiromi FUCHIKAMI, Naoko TAKEDA, Nana NATSUME, Masahiro KATO
    Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association).2023; 84(2): 238.     CrossRef
  • Identification of key breast features using a neural network: applications of machine learning in the clinical setting of Plastic Surgery
    Nitzan Kenig, Javier Monton Echeverria, Luis De la Ossa
    Plastic & Reconstructive Surgery.2023;[Epub]     CrossRef
  • Breast cancer patient-reported outcome of factors influencing cosmetic satisfaction after breast-conserving therapy
    A. T. P. M. Brands-Appeldoorn, A. J. G. Maaskant-Braat, L. Janssen, L. A. D. M. van Osch, V. C. G. Tjan-Heijnen, R. M. H. Roumen
    Breast Cancer.2022; 29(1): 114.     CrossRef
  • BROWSE: A multicentre comparison of nine year outcomes in acellular dermal matrix based and complete submuscular implant-based immediate breast reconstruction-aesthetics, capsular contracture and patient reported outcomes
    Rebecca L. Wilson, Cliona C. Kirwan, Joe M. O'Donoghue, Richard A. Linforth, Richard K. Johnson, James R. Harvey
    European Journal of Surgical Oncology.2022; 48(1): 73.     CrossRef
  • Factors related to patient-reported cosmetic outcome after breast-conserving therapy for breast cancer
    A. T. P. M. Brands-Appeldoorn, R. C. M. Thomma, L. Janssen, A. J. G. Maaskant-Braat, V. C. G. Tjan-Heijnen, R. M. H. Roumen
    Breast Cancer Research and Treatment.2022; 191(3): 545.     CrossRef
  • Adaptation of BCCT Learning Model in Developing Religious Aspects of Children
    Abd Hamid Wahid, Muhammad Fajri, Hasan Baharun, Riana Imroatul Fitriyah, Arifatur Risqiyah
    Jurnal Obsesi : Jurnal Pendidikan Anak Usia Dini.2022; 6(4): 3439.     CrossRef
  • Methods of Esthetic Assessment after Adjuvant Whole-Breast Radiotherapy in Breast Cancer Patients: Evaluation of the BCCT.core Software and Patients’ and Physicians’ Assessment from the Randomized IMRT-MC2 Trial
    Tobias Forster, Clara Köhler, Melissa Dorn, Matthias Felix Häfner, Nathalie Arians, Laila König, Semi Ben Harrabi, Ingmar Schlampp, Eva Meixner, Vanessa Heinrich, Nicola Weidner, Michael Golatta, André Hennigs, Jörg Heil, Holger Hof, David Krug, Jürgen De
    Cancers.2022; 14(12): 3010.     CrossRef
  • Feasibility of anomaly score detected with deep learning in irradiated breast cancer patients with reconstruction
    Dong-Yun Kim, Soo Jin Lee, Eun-Kyu Kim, Eunyoung Kang, Chan Yeong Heo, Jae Hoon Jeong, Yujin Myung, In Ah Kim, Bum-Sup Jang
    npj Digital Medicine.2022;[Epub]     CrossRef
  • Breast Oncoplastic Resections: No Innovation Without Evaluation
    Sherif Monib, Mohamed Farag, Mohamed Ibrahim
    Indian Journal of Surgery.2021; 83(S2): 409.     CrossRef
  • Cosmetic Outcomes of a Phase 1 Dose Escalation Study of 5-Fraction Stereotactic Partial Breast Irradiation for Early Stage Breast Cancer
    Asal Rahimi, Howard E. Morgan, Dong W. Kim, Yuanyuan Zhang, Marilyn Leitch, Rachel Wooldridge, Sally Goudreau, Barbara Haley, Roshni Rao, Aeisha Rivers, Ann E. Spangler, Ryan T. Jones, Stella Stevenson, Jason Staley, Kevin Albuquerque, Chul Ahn, Sarah Neu
    International Journal of Radiation Oncology*Biology*Physics.2021; 110(3): 772.     CrossRef
  • Comparative study between laparoscopically harvested omental flap and glandular flap in immediate reconstruction after conservative surgery in breast cancer
    Waleed Y. El‐Sherpiny, Abdulhamid M. Abdelshafi, Mohamed Ghazaly, Ayman A. Elnemr, Ahmed A. Darwish, Mohamed A. Mlees
    Surgical Practice.2021; 25(2): 92.     CrossRef
  • Reliability of the BCCT.core software in evaluation of breast cosmesis – A systematic review
    Stami Trakis, Heidi Lord, Peter Graham, Ritin Fernandez
    Journal of Medical Imaging and Radiation Oncology.2021; 65(6): 817.     CrossRef
  • New criteria for breast symmetry evaluation after breast conserving surgery for cancer
    RENÉ ALOISIO DA COSTA VIEIRA, GABRIELE BILLER, FABIOLA CRISTINA BRANDINI DA SILVA, JONATHAS JOSÉ DA SILVA, MARCO ANTÔNIO DE OLIVEIRA, ANTÔNIO BAILÃO-JUNIOR
    Revista do Colégio Brasileiro de Cirurgiões.2021;[Epub]     CrossRef
  • Use of Symmetry Assessment Methods in the Context of Breast Surgery
    Javier Monton, Asia Torres, Maria Gijon, Luis Chang-Azancot, Nitzan Kenig, P. Camelia Trandafir, Joaquin Jordan, Ricardo Insausti
    Aesthetic Plastic Surgery.2020; 44(5): 1440.     CrossRef
  • Visual Breast Asymmetry Assessment with Optical-Flow Algorithm
    Javier Monton, Nitzan Kenig, Ricardo Insausti, Joaquin Jordan
    Journal of Medical Systems.2020;[Epub]     CrossRef
  • Nueva metodología para medir simetría frontal en pacientes reconstruidas por cáncer de mama
    Lenia Sánchez Wals, Carlos Acosta-Batista, Oscar Luis Vera Pérez, Juan Jesús Lence Anta, Marco Marcasciano
    Revista de Senología y Patología Mamaria.2019; 32(4): 133.     CrossRef
  • Objective assessment of flap volume changes and aesthetic results after adjuvant radiation therapy in patients undergoing immediate autologous breast reconstruction
    Yujin Myung, Yousung Son, Tae-hyun Nam, Eunyoung Kang, Eun-Kyu Kim, In Ah Kim, Keun-Yong Eom, Chan Yeong Heo, Jae Hoon Jeong, Fabio Santanelli, di Pompeo d'Illasi
    PLOS ONE.2018; 13(5): e0197615.     CrossRef
  • 21,651 View
  • 122 Download
  • 21 Web of Science
  • 22 Crossref
Close layer

Cancer Res Treat : Cancer Research and Treatment
Close layer
TOP